Ribozyme-mediated compensatory induction of menin-oncosuppressor function in primary fibroblasts from MEN1 patients

E Luzi1, F Marini, I Tognarini

  • 1Department of Internal Medicine, Metabolic Bone Unit, Regional Center for Hereditary Endocrine Tumors, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.

Cancer Gene Therapy
|August 14, 2010
PubMed

Insights

Multiple endocrine neoplasia type 1 (MEN1) involves tumors due to MEN1 gene mutations. Wild-type MEN1 gene expression compensates for mutations post-transcriptionally, suggesting potential RNA-based therapies.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Genetics

Background:

  • Multiple endocrine neoplasia type 1 (MEN1) syndrome is a genetic disorder characterized by tumors in parathyroid glands, gastroenteropancreatic neuroendocrine cells, and anterior pituitary.
  • The MEN1 gene encodes the menin tumor suppressor protein, and loss of heterozygosity at 11q13 is a hallmark of MEN1-associated tumors.

Purpose of the Study:

  • To investigate the expression of MEN1 mRNA and menin protein in fibroblasts from MEN1 patients with specific mutations.
  • To elucidate the post-transcriptional regulatory mechanisms of MEN1 gene expression in the context of disease.

Main Methods:

  • Analysis of MEN1 mRNA and menin protein expression in fibroblasts from normal individuals and MEN1 patients.
  • Utilizing small-interfering RNA (siRNA) and ribozyme silencing to manipulate MEN1 alleles.
  • Employing gel-retardation assays to study RNA-protein interactions.

Main Results:

  • Full-length menin protein expression was comparable between MEN1 and normal fibroblasts.
  • MEN1 patients showed expression of wild-type MEN1 alleles, with mutant alleles undergoing degradation via nonsense-mediated mRNA decay.
  • Silencing wild-type MEN1 mRNA abolished compensation, while silencing mutant MEN1 mRNA enhanced wild-type expression, indicating post-transcriptional compensation.

Conclusions:

  • MEN1 gene mutation carriers exhibit post-transcriptional upregulation of wild-type menin expression as a compensatory mechanism.
  • These findings provide insights into MEN1 tumorigenesis and support the development of RNA-based therapeutic strategies for MEN1.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Ribozymes02:47

Ribozymes

The term ribozyme is used for RNA that can act as an enzyme. Ribozymes are mainly found in selected viruses, bacteria, plant organelles, and lower eukaryotes. Ribozymes were first discovered in 1982 when Tom Cech’s laboratory observed Group I introns acting as enzymes. This was shortly followed by the discovery of another ribozyme, Ribonulcease P, by Sid Altman’s laboratory. Both Cech and Altman received the Nobel Prize in chemistry in 1989 for their work on ribozymes.
Ribozymes can be...
Ribozymes02:47

Ribozymes

The term ribozyme is used for RNA that can act as an enzyme. Ribozymes are mainly found in selected viruses, bacteria, plant organelles, and lower eukaryotes. Ribozymes were first discovered in 1982 when Tom Cech’s laboratory observed Group I introns acting as enzymes. This was shortly followed by the discovery of another ribozyme, Ribonulcease P, by Sid Altman’s laboratory. Both Cech and Altman received the Nobel Prize in chemistry in 1989 for their work on ribozymes.
Ribozymes can be...